Literature DB >> 7949749

A comparison of the effects of oestrogen/progestogen, high-dose oral calcium, intermittent cyclic etidronate and an ADFR regime on calcium kinetics and bone mass in postmenopausal women with spinal osteoporosis.

C Hasling1, P Charles, F T Jensen, L Mosekilde.   

Abstract

The effects of four different treatments for osteoporosis were compared in a prospective, randomized, 3-year study in 74 postmenopausal women with spinal crush fracture osteoporosis. Patients were randomly assigned to cyclic oestrogen/progestogen therapy (group 1, n = 20), a daily oral calcium dose of 2 g (group 2, n = 17), intermittent cyclic etidronate therapy (group 3, n = 19), or an ADFR treatment with triiodothyronine as activator and etidronate as depressor (group 4, n = 18). Spine and forearm bone mineral content was measured before entry and every 30 weeks. Combined calcium balance and 47Ca kinetic studies were performed before and after 1 and 3 years of treatment. Bone turnover, estimated by serum alkaline phosphatase and renal hydroxyproline excretion, decreased in all four groups during the first half of the treatment period but remained reduced during the second half in groups 1 and 3 only. Group 1 had a significantly positive calcium balance after 60 weeks of treatment. After 150 weeks, the positive effect on calcium balance was significant and greater in groups 1 and 3 than in the other groups. This was achieved by a greater reduction in resorption rate in group 1 at week 60 and in groups 1 and 3 at week 150 as compared with the other groups. Only group 1 had a significant increase in spinal bone mass while a decrease in bone mass at the distal forearm was observed in the etidronate-treated group. We conclude that treatment of postmenopausal osteoporosis with oestrogen/progestogen for 3 years results in net spinal bone gain and a positive effect on calcium balance slightly better than that of intermittent etidronate. These effects were inferior in the groups receiving a large calcium supplementation or the ADFR group where no change in calcium balance or bone mass was found.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7949749     DOI: 10.1007/bf01623239

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN: 0937-941X            Impact factor:   4.507


  41 in total

1.  The effects of etidronate on trabecular bone remodeling in postmenopausal spinal osteoporosis: a randomized study comparing intermittent treatment and an ADFR regime.

Authors:  T Steiniche; C Hasling; P Charles; E F Eriksen; F Melsen; L Mosekilde
Journal:  Bone       Date:  1991       Impact factor: 4.398

Review 2.  Treatment of osteoporoses by manipulation of coherent bone cell populations.

Authors:  H M Frost
Journal:  Clin Orthop Relat Res       Date:  1979-09       Impact factor: 4.176

3.  Recommended methods for the determination of four enzymes in blood.

Authors: 
Journal:  Scand J Clin Lab Invest       Date:  1974-06       Impact factor: 1.713

4.  17 Beta-estradiol and continuous norethisterone: a unique treatment for established osteoporosis in elderly women.

Authors:  C Christiansen; B J Riis
Journal:  J Clin Endocrinol Metab       Date:  1990-10       Impact factor: 5.958

5.  Effect of propranolol treatment on bone mass, bone mineral content, bone remodelling, parathyroid function and vitamin D metabolism in hyperthyroidism.

Authors:  L Mosekilde; B Jastrup; F Melsen; B Lund; B Lund; O H Sørensen; H E Nielsen; H Yde
Journal:  Eur J Clin Invest       Date:  1984-04       Impact factor: 4.686

6.  Calcium metabolism evaluated by 47Ca kinetics: estimation of dermal calcium loss.

Authors:  P Charles; F T Jensen; L Mosekilde; H H Hansen
Journal:  Clin Sci (Lond)       Date:  1983-10       Impact factor: 6.124

7.  Calcium metabolism in postmenopausal osteoporosis: the influence of dietary calcium and net absorbed calcium.

Authors:  C Hasling; P Charles; F T Jensen; L Mosekilde
Journal:  J Bone Miner Res       Date:  1990-09       Impact factor: 6.741

8.  Treatment of postmenopausal osteoporosis with transdermal estrogen.

Authors:  E G Lufkin; H W Wahner; W M O'Fallon; S F Hodgson; M A Kotowicz; A W Lane; H L Judd; R H Caplan; B L Riggs
Journal:  Ann Intern Med       Date:  1992-07-01       Impact factor: 25.391

9.  Exogenous triiodothyronine activates bone remodeling.

Authors:  C Hasling; E F Eriksen; P Charles; L Mosekilde
Journal:  Bone       Date:  1987       Impact factor: 4.398

10.  Effects of cyclical therapy for osteoporosis using an oral regimen of inorganic phosphate and sodium etidronate: a clinical and bone histomorphometric study.

Authors:  A B Hodsman
Journal:  Bone Miner       Date:  1989-01
View more
  5 in total

Review 1.  Management of the extremely preterm infant: is the replacement of estradiol and progesterone beneficial?

Authors:  A Trotter; L Maier; F Pohlandt
Journal:  Paediatr Drugs       Date:  2001       Impact factor: 3.022

2.  Ipriflavone prevents radial bone loss in postmenopausal women with low bone mass over 2 years.

Authors:  S Adami; L Bufalino; R Cervetti; C Di Marco; O Di Munno; L Fantasia; G C Isaia; U Serni; L Vecchiet; M Passeri
Journal:  Osteoporos Int       Date:  1997       Impact factor: 4.507

3.  Clinical effect of bisphosphonate and vitamin D on osteoporosis: reappraisal of a multicenter double-blind clinical trial comparing etidronate and alfacalcidol.

Authors:  Takuo Fujita; Hajime Orimo; Tetsuo Inoue; Kiyoshi Kaneda; Minoru Sakurai; Rikushi Morita; Kichizo Yamamoto; Yoichi Sugioka; Akio Inoue; Kunio Takaoka; Itsuo Yamamoto; Yuichi Hoshino; Hiroshi Kawaguchi
Journal:  J Bone Miner Metab       Date:  2007-02-26       Impact factor: 2.626

Review 4.  Do Calcium Supplements Predispose to Urolithiasis?

Authors:  Diomidis Kozyrakis; Dionysios Paridis; Anastasios Karatzas; Georgios Soukias; Zoi Dailiana
Journal:  Curr Urol Rep       Date:  2017-03       Impact factor: 3.092

5.  Association between inflammatory biomarkers and bone mineral density in a community-based cohort of men and women.

Authors:  Todd R Sponholtz; Xiaochun Zhang; Joao D T Fontes; James B Meigs; L Adrienne Cupples; Douglas P Kiel; Marian T Hannan; Robert R McLean
Journal:  Arthritis Care Res (Hoboken)       Date:  2014-08       Impact factor: 4.794

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.